Impacts of Medications on Microbiome-mediated Protection Against Enteric Pathogens

Overview

Journal Res Sq

Date 2024 Nov 1

PMID 39483881

Authors

Aman Kumar

Ruizheng Sun

Bettina Habib

Natasha A Bencivenga-Barry

Ivaylo I Ivanov

Robyn Tamblyn

Andrew L Goodman

Affiliations

Soon will be listed here.

Abstract

The majority of people in the U.S. manage health through at least one prescription drug. Drugs classified as non-antibiotics can adversely affect the gut microbiome and disrupt intestinal homeostasis. Here, we identified medications associated with an increased risk of GI infections across a population cohort of more than 1 million individuals monitored over 15 years. Notably, the cardiac glycoside digoxin and other drugs identified in this epidemiological study are sufficient to alter microbiome composition and risk of subsp. Typhimurium (. Tm) infection in mice. The impact of digoxin treatment on Tm infection is transmissible via the microbiome, and characterization of this interaction highlights a digoxin-responsive β-defensin that alters microbiome composition and consequent immune surveillance of the invading pathogen. Combining epidemiological and experimental approaches thus provides an opportunity to uncover drug-host-microbiome-pathogen interactions that increase infection risk in humans.

References

Kuznetsov D, Tegenfeldt F, Manni M, Seppey M, Berkeley M, Kriventseva E . OrthoDB v11: annotation of orthologs in the widest sampling of organismal diversity. Nucleic Acids Res. 2022; 51(D1):D445-D451. PMC: 9825584. DOI: 10.1093/nar/gkac998. View

Walker R, Vlamakis H, Lee J, Besse L, Xanthakis V, Vasan R . Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease. Genome Med. 2021; 13(1):188. PMC: 8680346. DOI: 10.1186/s13073-021-01007-5. View

Khosravi A, Mazmanian S . Disruption of the gut microbiome as a risk factor for microbial infections. Curr Opin Microbiol. 2013; 16(2):221-7. PMC: 5695238. DOI: 10.1016/j.mib.2013.03.009. View

Bohnhoff M, Drake B, Miller C . Effect of streptomycin on susceptibility of intestinal tract to experimental Salmonella infection. Proc Soc Exp Biol Med. 1954; 86(1):132-7. DOI: 10.3181/00379727-86-21030. View

Lewer D, Eastwood B, White M, Brothers T, McCusker M, Copeland C . Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study. PLoS Med. 2021; 18(10):e1003759. PMC: 8491890. DOI: 10.1371/journal.pmed.1003759. View

Que J, Hentges D . Effect of streptomycin administration on colonization resistance to Salmonella typhimurium in mice. Infect Immun. 1985; 48(1):169-74. PMC: 261931. DOI: 10.1128/iai.48.1.169-174.1985. View

Semple F, Dorin J . β-Defensins: multifunctional modulators of infection, inflammation and more?. J Innate Immun. 2012; 4(4):337-48. PMC: 6784047. DOI: 10.1159/000336619. View

Kim S, Covington A, Pamer E . The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017; 279(1):90-105. PMC: 6026851. DOI: 10.1111/imr.12563. View

Kongkaew C, Sakunrag I, Jianmongkol P . Non-compliance with digoxin in patients with heart failure and/or atrial fibrillation: a systematic review and meta-analysis of observational studies. Arch Cardiovasc Dis. 2012; 105(10):507-16. DOI: 10.1016/j.acvd.2012.06.004. View

10.

Raffatellu M, Santos R, Verhoeven D, George M, Wilson R, Winter S . Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008; 14(4):421-8. PMC: 2901863. DOI: 10.1038/nm1743. View

11.

Frye M, Bargon J, Lembcke B, Wagner T, Gropp R . Differential expression of human alpha- and beta-defensins mRNA in gastrointestinal epithelia. Eur J Clin Invest. 2000; 30(8):695-701. DOI: 10.1046/j.1365-2362.2000.00696.x. View

12.

Pletcher M, Flaherman V, Najafi N, Patel S, Rushakoff R, Hoffman A . Randomized Controlled Trials of Electronic Health Record Interventions: Design, Conduct, and Reporting Considerations. Ann Intern Med. 2020; 172(11 Suppl):S85-S91. DOI: 10.7326/M19-0877. View

13.

Nagashima K, Zhao A, Atabakhsh K, Bae M, Blum J, Weakley A . Mapping the T cell repertoire to a complex gut bacterial community. Nature. 2023; 621(7977):162-170. PMC: 10948025. DOI: 10.1038/s41586-023-06431-8. View

14.

Raffatellu M, George M, Akiyama Y, Hornsby M, Nuccio S, Paixao T . Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe. 2009; 5(5):476-86. PMC: 2768556. DOI: 10.1016/j.chom.2009.03.011. View

15.

Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S . Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. Cell. 2015; 163(2):367-80. PMC: 4765954. DOI: 10.1016/j.cell.2015.08.058. View

16.

Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman A . Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019; 363(6427). PMC: 6533120. DOI: 10.1126/science.aat9931. View

17.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson E . Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018; 555(7698):623-628. PMC: 6108420. DOI: 10.1038/nature25979. View

18.

Wagner S, Konigsmaier L, Lara-Tejero M, Lefebre M, Marlovits T, Galan J . Organization and coordinated assembly of the type III secretion export apparatus. Proc Natl Acad Sci U S A. 2010; 107(41):17745-50. PMC: 2955140. DOI: 10.1073/pnas.1008053107. View

19.

Lambert J, Zhao D, Meyers R, Kuester R, Timmermann B, Dorr R . Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. Toxicon. 2002; 40(12):1701-8. DOI: 10.1016/s0041-0101(02)00203-9. View

20.

Flannigan K, Ngo V, Geem D, Harusato A, Hirota S, Parkos C . IL-17A-mediated neutrophil recruitment limits expansion of segmented filamentous bacteria. Mucosal Immunol. 2016; 10(3):673-684. PMC: 5350071. DOI: 10.1038/mi.2016.80. View